All In Biotech

Drug Trial Radar · NCT05650580

TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors

A Phase I Clinical Study to Characterize Safety, Tolerability, and Pharmacokinetics of TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: May 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

26

Planned (sponsor's estimate)

Start

Apr 23, 2023

Primary completion

Jul 30, 2025

Study completion Dec 30, 2025

Sponsor

Lead sponsor
Tarapeutics Science Inc.Industry
Sponsor type
Industry
First posted
Dec 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase 1 dose escalation and expanded cohort study of TR115 in the treatment of adult patients with relapsed/refractory non-hodgkin's lymphoma or advanced solid tumors.

Conditions

  • Non-Hodgkin's Lymphoma, Relapsed
  • Non-Hodgkin's Lymphoma Refractory
  • Advanced Solid Tumor

Interventions

  • TR115Drug

    TR115 is supplied as tablet with dosage strength of 100mg. TR115 tablet will be administered orally on a continuous twice daily (BID) schedule and a treatment cycle is defined as 28 days for the purposes of scheduling procedures and evaluations. TR115 tablets will be given until there appears evidence of progressive disease , intolerable toxicity, or the subject discontinues from the study treatment for other reasons. Proposed daily dose (BID): 100mg, 200mg, 400mg, 800mg, 1200mg, 1600mg. It is possible for additional and/or intermediate dose levels to be added during the course of the study. Cohorts may be added at any dose level below the Maximum Tolerated Dose (MTD) in order to better understand safety, Pharmacokinetic (PK) or Pharmacodynamic (PD).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events and serious adverse eventsTime frame: from the first dose to within 30 days after the last dose
  2. dose limited toxicitiesTime frame: within 31 days after the first dose
  3. maximum tolerated doseTime frame: Throughout the study for approximately 2 years
  4. recommedded phase 2 doseTime frame: Throughout the study for approximately 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The first affiliated hospital, Zhejiang university school of medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.